Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103)

Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103)

Show other versions (1)

Background and objectives: ADV7103 is a new prolonged-release treatment for distal renal tubular acidosis (dRTA), containing potassium citrate and potassium bicarbonate. Since acidosis may affect bone mineral contents, the effects of ADV7103 on bone mineral density (BMD) and growth in patients with...

Full description

Bibliographic Details
Main Authors: Aurélia Bertholet-Thomas, Maria A. Manso-Silván, Victor Navas-Serrano, Catherine Guittet, Sophie Joukoff, Justine Bacchetta, Olivia Boyer, Mariano Rodriguez Portillo, Luc-André Granier
Format: Article
Language:Spanish
Published: Elsevier 2023-07-01
Series:Nefrología
Subjects:
ATRd
Bicarbonato plasmático
Calciuria
Citraturia
Crecimiento
Densidad mineral ósea
Online Access:http://www.sciencedirect.com/science/article/pii/S0211699522000406

Internet

http://www.sciencedirect.com/science/article/pii/S0211699522000406

Similar Items